Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This non-randomized phase II study is designed to assess the response rate and toxicity of
weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic
colorectal cancer.